Overview
Overview
Glutathione dosage protocols leverage this master antioxidant tripeptide (γ-L-glutamyl-L-cysteinyl-glycine) to support cellular detoxification, reduce oxidative stress, and maintain redox balance throughout the body[1][2]. As the most abundant intracellular thiol, glutathione plays a central role in neutralizing free radicals, supporting liver function, enhancing immune cell activity, and protecting against environmental toxins[3][4]. This educational protocol presents a subcutaneous injection a
- Category
- Longevity
- Routes
- subcutaneous
Mechanism
Glutathione
Mechanism of action
Mechanism of action
In plain English: glutathione is your cells' main cleanup molecule. It grabs onto unstable molecules called free radicals and neutralizes them before they damage cell parts. It also helps the liver tag and remove certain toxins so they can leave the body. The technical version: glutathione donates an electron from its cysteine sulfur group to neutralize reactive oxygen species. In doing so it becomes oxidized (GSSG), then an enzyme called glutathione reductase recycles it back to the active reduced form (GSH). The ratio of GSH to GSSG is a common lab marker of how much oxidative stress a cell is under. For skin specifically, glutathione blocks an enzyme called tyrosinase and nudges pigment cells toward making lighter pheomelanin instead of darker eumelanin. That is the mechanism behind the skin-lightening research — and also why regulators worry that lightening could reduce the skin's natural UV protection over time. One well-established clinical fact anchors all of this: when someone overdoses on acetaminophen (Tylenol), the liver burns through its glutathione detoxifying the drug. The antidote, N-acetylcysteine (NAC), works by refilling the cysteine your liver needs to rebuild glutathione. That is real, FDA-recognized pharmacology, and it explains why cysteine supply is the rate-limiting step for making glutathione.
Key research findings
- 01
Endogenous tripeptide (gamma-L-glutamyl-L-cysteinyl-glycine); the major low-molecular-weight intracellular thiol antioxidant in mammalian cells (well-established biochemistry).
- 02
Central to redox homeostasis, reactive-oxygen-species buffering, and phase-II detoxification via glutathione conjugation (glutathione-S-transferases) (extensively documented in vitro and in vivo).
- 03
The reduced/oxidized (GSH/GSSG) ratio is a widely used research marker of cellular redox/oxidative status.
- 04
Human studies: oral bioavailability is debated; research has compared oral, liposomal, and intravenous routes with mixed pharmacokinetic findings.
- 05
Blood and tissue glutathione levels are reported to decline with age and oxidative stress in multiple human and animal studies.
Primary source: Glutathione is among the most extensively studied biomolecules, with a deep and mature literature across biochemistry, cell biology, and human research; its core identity and redox/detoxification roles are well established. Open questions center on the bioavailability of administered glutathione and on functional endpoints, which remain actively studied.
Pharmacokinetic profile
Single-dose plasma curve over 24h. Shaded band = commonly-cited therapeutic window. Illustrative only.
Researched Effects
Researched benefits
Areas of active research and investigation. Results may vary and are based on preclinical or early clinical data.
Supports reduction of oxidative stress markers and maintenance of cellular redox balance[1][10].
May enhance liver function and support hepatic detoxification pathways[9][11].
Research suggests immune-modulating effects, including support for natural killer cell activity and T-cell function[3][12].
Clinical studies on skin health indicate potential effects on melanin index and skin brightness with sustained use[13][14].
Protocol Reference
Protocol reference
Commonly cited research range: 100–200 mg, daily_for_cycles.
Reference figures reported in the research literature — not a dosing recommendation. For interactive vial math and scheduling, see the Calculator and Schedule tabs.
Cited protocol & reconstitution guide
Source-backed reference fields by phase, including any volume fields authored in the cited guide.
Weeks 1–2
100 mg
Weeks 3–4
150 mg
Weeks 5–8
200 mg
| Phase | Reference amount | Units / volume |
|---|---|---|
| Weeks 1–2 | 100 mg | 33 units (0.33 mL) |
| Weeks 3–4 | 150 mg | 50 units (0.50 mL) |
| Weeks 5–8 | 200 mg | 67 units (0.67 mL) |
Titration protocol
- Oral capsuleStart250-1,000 mg/day
RCTs conflict on whether it raises body stores
- Liposomal / sublingualBuild~300-500 mg/day
Small studies suggest better absorption
- IntranasalBuild300-600 mg/day split x3
Safe in PD trials; did not beat placebo
- IV (clinic)Maintenance600-1,200 mg/session
Not FDA-approved cosmetically; safety concerns
Storage & Handling
Storage requirements(typical for most peptides)
Can be stored for extended periods. Protect from moisture.
Store in refrigerator door. Never freeze after reconstitution.
Label vials with reconstitution date. Discard if cloudy.
Reconstitution steps
- 01🌡️Draw 2.0 mL bacteriostatic water with a sterile syringe.
- 02🧴Inject slowly down the vial wall; avoid foaming.
- 03💉Gently swirl/roll until dissolved (do not shake).
- 04💧Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
- 05🔄Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Additional storage notes
Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
Refrigerate at 2–8 °C (35.6–46.4 °F); use promptly and avoid freeze–thaw .
Allow vials to reach room temperature before opening to reduce condensation uptake.
Glutathione is relatively unstable once reconstituted—use within 2–3 weeks for optimal potency [6] .
Clinical Evidence
Clinical evidence
Well characterized in biochemistry; research examines redox balance, detoxification, and oxidative-stress pathways.
Glutathione is among the most extensively studied biomolecules, with a deep and mature literature across biochemistry, cell biology, and human research; its core identity and redox/detoxification roles are well established. Open questions center on the bioavailability of administered glutathione and on functional endpoints, which remain actively studied.
- 01Endogenous tripeptide (gamma-L-glutamyl-L-cysteinyl-glycine); the major low-molecular-weight intracellular thiol antioxidant in mammalian cells (well-established biochemistry).
- 02Central to redox homeostasis, reactive-oxygen-species buffering, and phase-II detoxification via glutathione conjugation (glutathione-S-transferases) (extensively documented in vitro and in vivo).
- 03The reduced/oxidized (GSH/GSSG) ratio is a widely used research marker of cellular redox/oxidative status.
- 04Human studies: oral bioavailability is debated; research has compared oral, liposomal, and intravenous routes with mixed pharmacokinetic findings.
- 05Blood and tissue glutathione levels are reported to decline with age and oxidative stress in multiple human and animal studies.
Evidence maturity varies by compound; much peptide research is preclinical (in vitro or animal-model). Where human data are limited, findings should be read as research observations, not clinical conclusions.
References
Literature references
Published research articles and sources related to Glutathione.
- 01Richie JP Jr, Nichenametla S, Neidig W, et al. Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. European Journal of Nutrition (2015)et al. (2015)
- 02Allen J, Bradley RD. Effects of oral glutathione supplementation on systemic oxidative stress biomarkers in human volunteers. Journal of Alternative and Complementary Medicine (2011)et al. (2011)
- 03Arjinpathana N, Asawanonda P. Glutathione as an oral whitening agent: a randomized, double-blind, placebo-controlled study. Journal of Dermatological Treatment (2012)et al. (2012)
- 04Handog EB, Datuin MS, Singzon IA. An open-label, single-arm trial of a glutathione lozenge as a skin-lightening agent in Filipino women. International Journal of Dermatology (2016)et al. (2016)
- 05Sarkar R, et al. Glutathione as a skin-lightening agent and in melasma: a systematic review. International Journal of Dermatology (2025)et al. (2025)
- 06Weschawalit S, Thongthip S, Phutrakool P, Asawanonda P. Glutathione and its antiaging and antimelanogenic effects. Clinical, Cosmetic and Investigational Dermatology (2017)et al. (2017)
- 07U.S. Food and Drug Administration. FDA highlights concerns with using dietary ingredient glutathione to compound sterile injectables (Compounding Alert). FDA Human Drug Compounding (2019)et al. (2019)
- 08Food and Drug Administration (Philippines). FDA Advisory No. 2019-182: Unsafe use of glutathione as skin-lightening agent. FDA Philippines (2019)et al. (2019)
- 09Honda Y, Kessoku T, Sumida Y, et al. Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study. BMC Gastroenterology (2017)et al. (2017)
- 10Mischley LK, Lau RC, Shankland EG, Wilbur TK, Padowski JM. Phase IIb study of intranasal glutathione in Parkinson's disease. Journal of Parkinson's Disease (2017)et al. (2017)
- 11Mischley LK, Leverenz JB, Lau RC, et al. A randomized, double-blind phase I/IIa study of intranasal glutathione in Parkinson's disease. Movement Disorders (2015)et al. (2015)
- 12Schmitt B, et al. A targeted metabolomic assessment of oral glutathione bioavailability and safety in humans: a randomized crossover clinical trial. Antioxidants (2026)et al. (2026)
- 13Pedre B, et al. Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione. Pharmacology & Therapeutics (2013)et al. (2013)
Observed Effects
Observed effects in cited research
Oral and liposomal
- Oral glutathione is generally well tolerated in trials. Reported effects are usually mild: bloating, loose stools, or cramping. In the long oral skin-lightening and body-store trials, lab markers (liver enzymes, kidney values) stayed normal. Some reviews note theoretical concern that lightening skin could lower natural UV protection.
IV and injectable
- This is where the serious risks live. In one IV skin-lightening study, about 40% of participants reported abdominal cramps, 32% had deranged liver function tests, and 16% had diarrhea or tingling. Case reports describe anaphylaxis, severe systemic inflammation, acute liver injury, and one report of cardiomyopathy in a glutathione trial participant.
Quality and sterility risk
- The biggest injectable danger is not the molecule — it is the product. In January 2019, seven patients at one clinic had reactions within minutes of an IV glutathione infusion that the FDA linked to high endotoxin levels in the powder used to compound it. Unregulated injections also carry infection risks (HIV, hepatitis) when needles or facilities are not sterile.
Regulatory status
- As of June 2026, no injectable glutathione product is FDA-approved for skin lightening or general wellness in the United States. The FDA has warned against compounded IV glutathione, and the FDA Philippines issued a public advisory against IV glutathione for skin lightening.
- Sensitive-topic note: skin-lightening practices intersect with serious health, cultural, and self-image issues. If skin tone is causing distress, a dermatologist is a safer first stop than a clinic offering IV drips. This is a sensitive area; the safest information here is the information that keeps you away from unregulated injections.
Research Considerations
Research considerations
Research Use Only - not for human or veterinary therapeutic use. A well-characterized endogenous/biochemical compound; on this platform it is handled strictly as a research material. Consult a licensed healthcare professional for any clinical decisions.
- Pregnant or breastfeeding people: safety has not been established in trials; avoid unless a clinician advises otherwise.
- People with asthma: inhaled/nebulized glutathione has triggered bronchospasm in some reports; the nasal route in Parkinson's trials was separate and monitored.
- Anyone considering IV/injectable glutathione: highest risk group. Sterility, dosing, and product purity problems have caused serious harm.
- People on medications metabolized by the liver: glutathione is part of liver detox pathways; discuss interactions with a clinician.
- G6PD deficiency: relevant when IV glutathione is paired with high-dose IV vitamin C, which the FDA Philippines flagged.
Factors noted in the research literature; not patient-specific medical advice.
Regulatory Status
Regulatory status
RUO
Comparisons
Comparisons
| Compound | Mechanism | Route | Status |
|---|---|---|---|
| Glutathionethis | An endogenous tripeptide (gamma-L-glutamyl-L-cysteinyl-glycine) functioning as a major intracellular antioxidant and redox buffer, supporting phase-II detoxification conjugation and neutralization of reactive oxygen species. | subcutaneous | Investigational / RUO |
| Livagen | A synthetic tetrapeptide bioregulator (Lys-Glu-Asp-Ala) studied for peptidase modulation and epigenetic/chromatin effects (e.g., heterochromatin decondensation) in aging cell models. | subcutaneous | Investigational / RUO |
| NAD+ | An essential coenzyme central to cellular energy metabolism (redox reactions) and mitochondrial function, and a substrate for sirtuins and PARPs in DNA-repair and signaling pathways. | subcutaneous | Investigational / RUO |
| Prostamax | A synthetic tetrapeptide bioregulator (Lys-Glu-Asp-Pro) derived from prostate peptide-complex research, studied for tissue-specific regulatory effects on prostate tissue. | intramuscular | Investigational / RUO |
| SNAP-8 | A synthetic acetylated octapeptide (an extended Argireline analog) studied for topical reduction of muscle contraction by interfering with SNARE-complex formation at the neuromuscular junction. | subcutaneous | Investigational / RUO |
| Gonadorelin | A synthetic form of gonadotropin-releasing hormone (GnRH) acting on pituitary GnRH receptors to stimulate luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release, supporting the hypothalamic-pituitary-gonadal axis. | subcutaneous | Investigational / RUO |
| HCG | A glycoprotein hormone that binds LH receptors in the gonads, mimicking luteinizing hormone with a substantially longer half-life to stimulate gonadal steroidogenesis. | subcutaneous | Investigational / RUO |
Attributes shown for research comparison only; not a statement of efficacy or therapeutic equivalence.
FAQ
Frequently asked questions
Glutathione is the most abundant antioxidant your body makes on its own. It is a tripeptide built from cysteine, glycine, and glutamate. It neutralizes free radicals, helps the liver remove certain toxins, and supports the recycling of other antioxidants. Cells measure stress partly by the ratio of active (GSH) to spent (GSSG) glutathione.
Human oral trials have most often used 250 mg to 1,000 mg per day, with skin-lightening RCTs frequently using 500 mg/day for 4 to 12 weeks. These are study amounts, not a personal recommendation, and glutathione is not an FDA-approved drug for these uses. Talk to a clinician about what is appropriate for you.
This is genuinely debated. A 2015 six-month RCT found oral glutathione raised body stores at 250 and 1,000 mg/day. But a 2011 RCT at 500 mg twice daily found no change, and a 1992 single 3 g dose did nothing. The gut enzyme gamma-glutamyltransferase breaks glutathione down, which is why liposomal and sublingual forms were created.
Small studies suggest liposomal and sublingual forms raise whole-blood glutathione more than plain capsules, because the lipid coating helps it survive digestion. However, many of these studies are small and funded by the formulation makers, and dramatic claims like "64x more bioavailable" should be treated cautiously until larger independent trials confirm them.
Oral glutathione is generally well tolerated in trials, with mild effects like bloating or loose stools. IV and injectable glutathione is a different risk category: it is not FDA-approved for cosmetic use, and the FDA issued a 2019 alert after seven patients reacted to a contaminated compounded injection. Reactions have included anaphylaxis and liver injury.
In several oral RCTs at 250-500 mg/day, glutathione produced a modest, statistically significant drop in melanin index versus placebo, with effects appearing in 2-4 weeks. The lightening was temporary and reversed after stopping. It works by inhibiting tyrosinase and shifting pigment toward lighter pheomelanin. This is a cosmetic effect, not a health benefit, and regulators have raised UV-protection concerns.
Glutathione for skin lightening is given by clinics intravenously, not by patients at home. Self-injection is strongly discouraged: IV glutathione is not FDA-approved for cosmetic use, and unregulated or contaminated products have caused serious harm including endotoxin reactions and infections. If you are considering it, talk to a licensed clinician rather than attempting it yourself.
Yes. When the liver processes acetaminophen, it uses up glutathione, and an overdose can deplete it dangerously. That is exactly why the hospital antidote for acetaminophen overdose is N-acetylcysteine (NAC), which refills the cysteine your liver needs to rebuild glutathione. This is well-established, FDA-recognized pharmacology.
Early human data is encouraging but limited. A 2017 pilot study gave 300 mg/day oral glutathione to NAFLD patients for four months and saw liver enzyme (ALT) levels fall, and a 2025 review of three small trials found similar improvements. These studies are small and not definitive, so glutathione is not a proven liver treatment.
There is not enough safety data to recommend glutathione supplements during pregnancy or breastfeeding. Most trials excluded pregnant participants. The safest course is to avoid it unless a qualified clinician specifically advises otherwise.
Many labels suggest an empty stomach, often in the morning, but this is convention rather than a proven requirement. Consistency over weeks matters more than time of day, since skin-pigmentation effects in trials took at least 4 weeks to appear and faded after stopping.
No. This is an educational research reference summarizing how glutathione has been studied and dosed. It is not medical advice, a treatment plan, or a recommendation to inject anything. Talk to a qualified clinician before using glutathione, especially by any injectable route.
Research-use notice
Research Use Only. This educational content and calculation support is intended for private research documentation. It does not provide medical advice, human-use directions, or claims of safety or effectiveness.